Qilian International Holding Group Ltd./$BGM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Qilian International Holding Group Ltd.

BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.

Ticker

$BGM
Sector
Health
Primary listing
NASDAQ

Employees

323
Headquarters
Chengdu, China
Website
www.bgmgroupltd.com

BGM Metrics

BasicAdvanced
$1.8B
-
-$0.20
-
-

Bulls say / Bears say

For the six months ended March 31, 2025, net revenue rose 14% to $14.31 million from $12.56 million a year earlier, while gross profit increased to $2.51 million from $1.41 million, reflecting improving top-line growth and margin expansion. (SEC Form 10-Q)
Total assets surged to $207.4 million as of March 31, 2025 from $53.0 million on September 30, 2024, driven by strategic acquisitions in AI solutions ($22.5 million) and insurance business ($30.9 million), diversifying the company's portfolio beyond pharmaceuticals. (SEC Form 10-Q)
On May 2, 2025, BGM announced the acquisition of HM Management for approximately US$41.7 million in an all-stock transaction to expand its AI application ecosystem and integrate AI capabilities into its insurance and mobility operations, bolstering its competitive position in the AI industry. (PR Newswire)
The company reported an operating loss of $2.24 million for the six months ended March 31, 2025 versus a $0.68 million loss in the prior year period, indicating continued unprofitability in core operations despite revenue growth. (SEC Form 10-Q)
Selling, general and administrative plus research and development expenses totaled $4.75 million for H1 2025, representing over 33% of net revenue, which strains profitability given the company's limited scale. (SEC Form 10-Q)
Goodwill arising from the November 2024 acquisition of its AI and insurance business amounted to $135.2 million, significantly exceeding the $4.75 million of net assets acquired, posing a heightened risk of future impairment charges. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BGM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs